A single-center, randomized, open-label, two-period, crossover, fasted bioequivalence study: comparing recombinant human follicle-stimulating hormone for injection (JZB30) with Gonal-f® in healthy Chinese female participants

Zhuo Chen, Qin Yu, Shiyin Feng, Mo Li, Linrui Cai, Chunfeng Du, Dan Du, Qin ZouFrontiers in Pharmacology 2025 · DOI

TL;DR

Researchers have successfully demonstrated that JZB30, a new biosimilar candidate for recombinant human follicle-stimulating hormone (rhFSH), is pharmacokinetically equivalent to the industry standard, Gonal-f®. In a rigorous crossover study of 48 healthy Chinese women, JZB30 showed matching absorption and exposure profiles with a high safety margin and low risk of immunogenicity.

What Problem Does This Paper Address?

Infertility is a growing global health challenge, and Assisted Reproductive Technology (ART) often relies on follicle-stimulating hormone (FSH) to induce the development of multiple ovarian follicles. While Gonal-f® has been the "gold standard" rhFSH treatment since the late 90s, its high cost can limit patient access.

Developing biosimilars—biological products highly similar to an already approved reference drug—is the primary strategy for increasing affordability. However, rhFSH is a complex glycoprotein. Proving that a new version (like JZB30) behaves identically in the human body requires precise clinical trials to ensure that differences in manufacturing don't lead to altered drug behavior or unexpected immune responses.

Methods

The authors conducted a single-center, randomized, open-label, two-period crossover study.

  • The Cohort: 48 healthy adult Chinese female participants.
  • The Challenge of Endogenous FSH: Because women naturally produce FSH, the researchers had to "silence" the participants' own hormone production to accurately measure the injected drug. They used a downregulation phase involving a single injection of triptorelin (a GnRH agonist) to suppress endogenous FSH levels to ≤4 IU/L.
  • The Crossover: Participants were split into two groups. One received JZB30 first, followed by Gonal-f® after a washout period; the other group received them in reverse order.
  • Dosing: A single subcutaneous injection of 225 IU (16.5 μg).
  • Analysis: Blood samples were taken at 18 specific time points over 168 hours. FSH concentrations were measured using a validated electrochemiluminescence immunoassay (ECLIA), and pharmacokinetic (PK) parameters were calculated using a non-compartmental model.

Datasets

As this is a clinical trial, the primary "dataset" consists of the physiological and blood-concentration data from the 48 enrolled participants (with 47 completing the full study). The trial was registered on ClinicalTrials.gov under the identifier NCT06778304.

Key Insights and Ideas

  • Baseline Correction is Critical: Because FSH is an endogenous substance, the researchers used the arithmetic mean of pre-dose measurements to "zero" the data. This allowed them to isolate the PK signal of the injected drug from the residual background noise of the body's natural hormones.
  • Glycoprotein Complexity: Unlike simple small-molecule drugs, rhFSH's effectiveness is tied to its complex sugar chains (glycosylation). The fact that JZB30’s PK profile matched Gonal-f® so closely suggests that the manufacturing process at Chengdu Jingze Biopharmaceutical successfully replicated these complex biological structures.
  • Transient Immunogenicity: One participant tested positive for anti-FSH antibodies after receiving the reference drug (Gonal-f®), but the response disappeared within six months without intervention. This highlights that even established biologics can trigger minor immune "blips" that don't necessarily impact safety or efficacy.

Key Results

The study met all predefined criteria for bioequivalence. For a drug to be considered bioequivalent, the 90% Confidence Interval (CI) of the Geometric Mean Ratio (GMR) between the test and reference drug must fall between 80% and 125%.

  • Cmax (Peak Concentration): GMR of 106.12% (90% CI: 101.92%–110.49%).
  • AUC0-t (Total Exposure over time): GMR of 108.04% (90% CI: 104.13%–112.09%).
  • AUC0-∞ (Total Exposure extrapolated to infinity): GMR of 115.32% (90% CI: 106.47%–124.90%).
  • Safety: All adverse events (AEs) were mild (Grade 1) and resolved spontaneously. The most common AEs were related to the reproductive system (e.g., vaginal bleeding), which is expected given the nature of the hormone.

Limitations and Future Work

While this study confirms that JZB30 moves through the body like Gonal-f®, it was conducted on healthy volunteers rather than patients undergoing actual infertility treatment. Healthy volunteers provide a "cleaner" PK signal, but they don't reflect the physiological complexities of patients with ovarian dysfunction.

The authors note that the next step is Phase III clinical trials. These will evaluate JZB30’s actual clinical efficacy—specifically its ability to stimulate follicle growth and lead to successful pregnancies—in the target patient population. Additionally, long-term immunogenicity needs to be monitored over multiple treatment cycles.

Summary updated

Abstract

The trial was registered on ClinicalTrials.gov under identifier NCT06778304.
BibTeX
@inproceedings{chen2025single,
  author = {Zhuo Chen and Qin Yu and Shiyin Feng and Mo Li and Linrui Cai and Chunfeng Du and Dan Du and Qin Zou},
  title = {{A single-center, randomized, open-label, two-period, crossover, fasted bioequivalence study: comparing recombinant human follicle-stimulating hormone for injection (JZB30) with Gonal-f® in healthy Chinese female participants}},
  booktitle = {Frontiers in Pharmacology},
  year = {2025},
  doi = {10.3389/fphar.2025.1678830},
}
Figure